Sinopharm's China National Accord Reports Q3 Net Profit of 346 Million Yuan, Up 18.91% Year-on-Year

Stock News10-20

SINOPHARM (01099) announced that China National Accord Medicines Corporation Ltd. recorded total operating revenue of approximately 55.066 billion yuan for the first three quarters of 2026, representing a year-on-year decline of 0.11%.

Net profit attributable to shareholders of the listed company stood at approximately 952 million yuan, down 0.48% compared with the same period last year, while basic earnings per share came in at 1.56 yuan.

In the third quarter of 2026 alone, the company generated operating revenue of 18.800 billion yuan, up 2.57% year-on-year, and net profit attributable to shareholders of the listed company reached 346 million yuan, an increase of 18.91% year-on-year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment